The impact of body-mass index on new metabolic indices between classical and nonclassical phenotypes of polyendocrine metabolic ovarian syndrome (PMOS)

Şerife Ezgi Doğan; Özge Yücel Çelik

doi:10.32322/jhsm.1963841

The impact of body-mass index on new metabolic indices between classical and nonclassical phenotypes of polyendocrine metabolic ovarian syndrome (PMOS)

Abstract

Aims: The purpose of this study is to identify relationship between new metabolic indices -namely Triglyceride Glucose Index (TyG), lipid accumulation product (LAP), and Visceral Adiposity Index (VAI) are investigated-and classical and nonclassical polyendocrine metabolic ovarian syndrome (PMOS) phenotypes. Methods: Data were evaluated retrospectively which collected from 103 patients with PMOS (59 classical phenotypes, 44 nonclassical phenotypes). Results: Classical phenotypes group has higher body-mass index (BMI), weight, waist circumference, waist height ratio, LH levels, TyG, LAP and VAI levels than non-classical phenotypes. In according to lipid profiles, classical PMOS group has more atherogenic trend. The difference between groups in TyG, LAP and VAI is eliminated after adjustment for BMI. Conclusion: Since BMI adjustment eliminates metabolic differences between classical and non-classical phenotypes, therapeutic interventions may focus on weight loss and obesity treatment for all phenotypes of PMOS.

Keywords

Supporting Institution

The authors have indicated they have no financial relationships with any company and no external funding

Ethical Statement

All authors have completed and submitted the ICMJE Form for Disclosure of Potential

References

Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026. doi:10.1016/S0140-6736(26)00717-8
Helvaci N, Yildiz BO. The impact of ageing and menopause in women with polycystic ovary syndrome. Clin Endocrinol. 2022;97(3):371-382. doi:10.1111/CEN.14558
Morshed S, Banu H, Hossan S, Mahrukh H, Hasanat MA. Association of adiposity indices with insulin resistance among women with polycystic ovary syndrome. Clin Exp Reprod Med. 2025;52(4):342-347. doi:10.5653/cerm.2024.07388
Parsaei M, Karimi E, Barkhordarioon A, Yousefi M, Tarafdari A. Lipid accumulation product and Visceral Adiposity Index in polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Lipids Health Disease. 2025;24(1):311. doi:10.1186/S12944-025-02719-Y
Seyedi SA, Nabipoorashrafi SA, Amin Afshari S, et al. Lipid Accumulation Product Index as a marker of metabolic syndrome in women with polycystic ovary syndrome: a systematic review and meta-analysis. Endocrinol Diabet Metabol. 2025;8(5):e70078. doi:10.1002/edm2.70078
Fauser BCJM, Tarlatzis, Fauser, et al. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction. 2004;19(1):41-47. doi:10.1093/HUMREP/DEH098
Nishida C, Ko GT, Kumanyika S. Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO Expert Consultation on Waist Circumference and Waist–Hip Ratio. Eur J Clin Nutrit. 2010;64:2-5. doi:10.1038/ejcn.2009.139
Yang HS, Kim SN, Lee S, Hur M. The validation of a novel, sex-specific LDL-cholesterol equation and the Friedewald, Sampson-NIH, and extended-Martin-Hopkins equations against direct measurement in Korean adults. Metabolites. 2025;15(1):18. doi:10.3390/metabo15010018

Bhattacharya K, Sengupta P, Dutta S, Chaudhuri P, Das Mukhopadhyay L, Syamal AK. Waist-to-height ratio and BMI as predictive markers for insulin resistance in women with PCOS in Kolkata, India. Endocrine. 2021;72(1):86-95. doi:10.1007/S12020-020-02555-3
Savran Üçok B, Dikici Aktaş T, Özalp E, et al. Comparative analysis of hormonal and metabolic indices in phenotypic subgroups of polycystic ovary syndrome. J Turk German Gynecol Assoc. 2026;27(1):29-35. doi:10.4274/jtgga.galenos.2026.2025-9-22
Cavnar Helvacı B, Hepşen S, Candemir B, Çakal E. Evaluating the triglyceride glucose index as a novel method for assessing insulin resistance in Turkish women with polycystic ovary syndrome. J Med Palliat Care. 2025;6(1):33-38. doi:10.47582/jompac.1601449
Nowak J, Jabczyk M, Borszcz J, Jagielski P, Zubelewicz-Szkodzińska B. Clinical utility of anthropometric parameters in identifying glucose dysregulation in women with polycystic ovary syndrome. Front Endocrinol. 2026;16:1756679. doi:10.3389/fendo.2025.1756679
Bilginer MC, Tüfekçi D, Emür Günay Y, et al. Evaluation of insulin resistance measurement methods in patients with polycystic ovary syndrome. Turk J Diab Obes. 2022;6(1):24-31. doi:10.25048/tudod.1041387
Dadachanji R, Patil A, Joshi B, Mukherjee S. Elucidating the impact of obesity on hormonal and metabolic perturbations in polycystic ovary syndrome phenotypes in Indian women. PLoS One. 2021;16(2):e0246862. doi:10.1371/journal.pone.0246862
Wen X, Wang L, Bai E. Metabolic characteristics of different phenotypes in reproductive-aged women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2024;15:1370578. doi:10.3389/fendo.2024.1370578
Bil E, Dilbaz B, Cirik DA, Ozelci R, Ozkaya E, Dilbaz S. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype. J Obstet Gynaecol Res. 2016;42(7):837-843. doi:10.1111/jog.12985
Pikee S, Shivani S, Jayshree B. Endocrine and metabolic profile of different phenotypes of polycystic ovarian syndrome. J Obstet Gynaecol India. 2016;66(suppl 1):560-566. doi:10.1007/s13224-016-0898-7
Rashidi H, Ramezani Tehrani F, Bahri Khomami M, Rostami Dovom M, Noroozzadeh M, Azizi F. The prevalence of various phenotypes of polycystic ovary syndrome: a community-based study in southwest of Iran. Iranian J Endocrinol Metabol. 2014;16(2):119-126.
Sobti S, Dewan R, Ranga S. Metabolic syndrome and insulin resistance in PCOS phenotypes. Int J Reprod Contracept Obstet Gynecol. 2017;6(11):5067-5073. doi:10.18203/2320-1770.ijrcog20175027
Singh N, Hooja N, Batar A, Jaiswal A, Bairwa P. A study of central fat accumulation indices amongst different polycystic ovary syndrome phenotypes. Int J Sci Res Arch. 2022;6(1):284-287. doi:10.30574/ijsra.2022.6.1.0132
Pluta D, Staśczak A, Stokowy T, Migacz M, Kochman K, Holecki M. Visceral adiposity index in relation to Rotterdam phenotypes of polycystic ovary syndrome. Biomedicines. 2025;13(8):1997. doi:10.3390/biomedicines13081997
Soares Jr JM, Hayashida SAY, Marcondes JAM, et al. Influence of phenotypes on the metabolic syndrome of women with polycystic ovary syndrome over a six-year follow-up in Brazil. Biomedicines. 2023;11(12):3262. doi:10.3390/biomedicines11123262
Akkus C, Oner O, Kilic AO, Duran C. Visceral adiposity index (VAI) levels and metabolic risk across phenotypes of polycystic ovary syndrome (PCOS). Medicina (Kaunas). 2025;61(9):1673. doi:10.3390/medicina61091673
Hosseinpanah F, Barzin M, Keihani S, Ramezani Tehrani F, Azizi F. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS prevalence study. Clin Endocrinol (Oxf). 2014;81(1):93-99. doi:10.1111/cen.12406
Gunay YE, Kişioğlu SV, Karakullukçu S, et al. Comparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groups. Rev Assoc Med Bras (1992). 2023;69(7):e20230174. doi:10.1590/1806-9282.20230174
Önal M, Çalı Öztürk H. Anti-Müllerian hormone and HOMA-IR in different phenotypes of polycystic ovary syndrome on insulin resistance. Anatolian Curr Med J. 2023;5(4):376-382. doi:10.38053/acmj.1323489
Javidan A, Azarboo A, Jalali S, et al. The association between Triglyceride-Glucose Index and polycystic ovary syndrome: a systematic review and meta-analysis across different populations. J Ovarian Res. 2025;18(1):163. doi:10.1186/s13048-025-01717-z
Radic L, Ognjanovic S, Popovic B, et al. The Triglyceride-Glucose (TyG) Index and its relation to metabolic indices in women with PCOS: a phenotype-based analysis. Endocr Abstr. 2025;110:P1039. doi:10.1530/endoabs.110.P1039
Božić-Antić I, Ilić D, Bjekić-Macut J, et al. Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome. Eur J Endocrinol. 2016;175(6):551-560. doi:10.1530/EJE-16-0775

Details

Primary Language

English

Subjects

Endocrinology

Journal Section

Research Article

Authors

Şerife Ezgi Doğan ^*
0000-0003-0526-7647
Türkiye

Özge Yücel Çelik
0000-0002-7746-1943
Türkiye

Publication Date

October 25, 2026

Submission Date

June 4, 2026

Acceptance Date

October 21, 2026

Published in Issue

Year 2026 Volume: 9 Number: 6

DOI

https://doi.org/10.32322/jhsm.1963841

IZ

https://izlik.org/JA99EM43HK

Cite

RIS / Bibtex

APA

Doğan, Ş. E., & Yücel Çelik, Ö. (2026). The impact of body-mass index on new metabolic indices between classical and nonclassical phenotypes of polyendocrine metabolic ovarian syndrome (PMOS). Journal of Health Sciences and Medicine, 9(6), 1909-1914. https://doi.org/10.32322/jhsm.1963841

AMA

1.Doğan ŞE, Yücel Çelik Ö. The impact of body-mass index on new metabolic indices between classical and nonclassical phenotypes of polyendocrine metabolic ovarian syndrome (PMOS). J Health Sci Med / JHSM. 2026;9(6):1909-1914. doi:10.32322/jhsm.1963841

Chicago

Doğan, Şerife Ezgi, and Özge Yücel Çelik. 2026. “The Impact of Body-Mass Index on New Metabolic Indices Between Classical and Nonclassical Phenotypes of Polyendocrine Metabolic Ovarian Syndrome (PMOS)”. Journal of Health Sciences and Medicine 9 (6): 1909-14. https://doi.org/10.32322/jhsm.1963841.

EndNote

Doğan ŞE, Yücel Çelik Ö (October 1, 2026) The impact of body-mass index on new metabolic indices between classical and nonclassical phenotypes of polyendocrine metabolic ovarian syndrome (PMOS). Journal of Health Sciences and Medicine 9 6 1909–1914.

IEEE

[1]Ş. E. Doğan and Ö. Yücel Çelik, “The impact of body-mass index on new metabolic indices between classical and nonclassical phenotypes of polyendocrine metabolic ovarian syndrome (PMOS)”, J Health Sci Med / JHSM, vol. 9, no. 6, pp. 1909–1914, Oct. 2026, doi: 10.32322/jhsm.1963841.

ISNAD

Doğan, Şerife Ezgi - Yücel Çelik, Özge. “The Impact of Body-Mass Index on New Metabolic Indices Between Classical and Nonclassical Phenotypes of Polyendocrine Metabolic Ovarian Syndrome (PMOS)”. Journal of Health Sciences and Medicine 9/6 (October 1, 2026): 1909-1914. https://doi.org/10.32322/jhsm.1963841.

JAMA

1.Doğan ŞE, Yücel Çelik Ö. The impact of body-mass index on new metabolic indices between classical and nonclassical phenotypes of polyendocrine metabolic ovarian syndrome (PMOS). J Health Sci Med / JHSM. 2026;9:1909–1914.

MLA

Doğan, Şerife Ezgi, and Özge Yücel Çelik. “The Impact of Body-Mass Index on New Metabolic Indices Between Classical and Nonclassical Phenotypes of Polyendocrine Metabolic Ovarian Syndrome (PMOS)”. Journal of Health Sciences and Medicine, vol. 9, no. 6, Oct. 2026, pp. 1909-14, doi:10.32322/jhsm.1963841.

Vancouver

1.Şerife Ezgi Doğan, Özge Yücel Çelik. The impact of body-mass index on new metabolic indices between classical and nonclassical phenotypes of polyendocrine metabolic ovarian syndrome (PMOS). J Health Sci Med / JHSM. 2026 Oct. 1;9(6):1909-14. doi:10.32322/jhsm.1963841